Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 32011959.
- Also identified by DOI 10.18553/jmcp.2020.26.2.221 and PMC identifier 10391235.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
No funding supported the writing of this letter. The authors report no conflicts of interest related to the subject of this letter.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Breast Neoplasms